Biocytogen Boston Corporation was officially established in Wakefield, MA. With high standard animal facilities, strict quality control systems and talented scientists, Biocytogen Boston Corporation provides drug in vivo efficacy services using our unique animal models and gene targeting services based on ESC and/or EGE technologies
Biocytogen received C-round funding from CMB International Capital Corporation Limited, SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
Biocytogen officially provided B-NDG® mice, established a pharmacological efficacy service platform and an antibody drug R&D service platform
Biocytogen Jiangsu Animal Center was officially put into use
Biocytogen raised B-round funding from SDIC Venture Capital and BioVeda China Fund
Biocytogen Jiangsu Co., Ltd. was founded in Haimen, Jiangsu, China.
BioVeda China invsted in Biocytogen. BioVeda China has extensive investment and management experience in biotechnology and pharmaceuticals, focusing on investing in fast growing companies with high technology and outstanding research and management teams. The investment from BioVeda greatly promoted Biocytogen's growth and development.
Beijing Biocytogen Co., Ltd. moved to Yizhuang Biomedical Park in Beijing Economic and Technological Development Zone. The new site covers an area of more than 2,000 square meters, including 3 molecular biology laboratories, 3 embryonic stem cell culture rooms, and 1 research and development office. The superior working environment and perfect supporting facilities provide a good foundation for Biocytogen to provide the fastest research and development services using genetic modified animal models.
Biocytogen's first project in China started on April 16, 2011 and ended on October 30, 2011 (obtained the heterozygous F1 mice). The fast timeline of less than 7 months, which is about half of the average timeline, greatly increased the company's competitiveness in the international market
Dr. Yuelei Shen established Beijing Biocytogen Co., Ltd. and served as the company's chairman and chief scientist.
With over 20 years experience in immunology, molecular biology and gene targeting animal models generation, Dr. Yuelei Shen established Biocytogen Biotechnology Company in the US and served as the President and CEO of the company. At that time, the company had developed a variety of mouse models, which had been licensed to nearly 100 universities, research institutes and pharmaceutical companies around the world.